Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
heart failure/protease
L'enllaç es desa al porta-retalls
13 resultats
Detecting diastolic heart failure by protease and protease inhibitor plasma profiling
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND
Despite significant advancements in high blood pressure (hypertension) medicines and the recognition that hypertension is a significant risk factor for the development of heart failure, this condition remains a major cardiovascular disease in the United States. One particular problem with
Protease inhibition for prevention or treatment of heart failure
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD
The present invention relates generally to treatment of contractile failure of the heart. More particularly, the present invention relates to the treatment of right ventricular (RV) contractile failure. In addition, this invention also relates to materials, methods and treatments for the
Predicting heart failure following myocardial infarction by protease and protease inhibitor profiling
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The Sequence Listing submitted Dec. 4, 2012 as a text file named "MUSC.sub.--10.sub.--8403_ST25.txt," created on Dec. 3, 2012, and having a size of 1,266 bytes is hereby incorporated by reference.
BACKGROUND
An important structural event following myocardial infarction (MI) is LV remodeling which
Peptidyl aminodiol renin inhibitors
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
TECHNICAL FIELD
The present invention relates to novel compounds and compositions which inhibit renin, processes for making such compounds, synthetic intermediates employed in these processes and a method of treating hypertension or congestive heart failure with such compounds or in combination with
Amino-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present invention relates to compounds of the formula I,
##STR00002## wherein A, D, E, G, R.sup.10, R.sup.11, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are
Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present invention relates to compounds of the formula I,
##STR00002## wherein A, D, E, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for
Biaryl-propionic acid derivatives and their use as pharmaceuticals
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This application claims the benefit of European Application No. EP13305402.3, filed Mar. 28, 2013, the disclosure of which is herein incorporated by reference in its entirety.
The present invention relates to compounds of the formula I,
##STR00002## wherein X, R, R1, R2, D, E.sub.1, E.sub.2,
Biaryl-propionic acid derivatives and their use as pharmaceuticals
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
This application claims the benefit of European Application No. EP13305401.5, filed Mar. 28, 2013, the disclosure of which is herein incorporated by reference in its entirety.
The present invention relates to compounds of the formula I,
##STR00002## wherein X, R, R1, R2, D, E.sub.1, E.sub.2,
3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present invention relates to compounds of the formula I,
##STR00002## wherein Ht, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful for the
Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present invention relates to compounds of the formula I,
##STR00002## wherein A, D, E, L, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful
Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present invention relates to compounds of the formula I,
##STR00002## wherein A, D, E, L, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful
Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present invention relates to compounds of the formula I,
##STR00002## wherein A, D, E, L, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are useful
Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The present invention relates to compounds of the formulae Ia and Ib,
##STR00002## wherein R1, R2, G, R.sup.10, R.sup.30, R.sup.40, R.sup.50 and R.sup.60 have the meanings indicated below, which are valuable pharmaceutical active compounds. They are inhibitors of the protease cathepsin A, and are
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
